Reata (RETA) - Gross Profit Margin

Official company branding of Reata Pharma (RETA)

Reata Pharmaceuticals management has successfully completed a merger with a global biotech behemoth, focusing on sales expansion. High barriers to entry in the rare pathology niche create a fierce struggle for monopoly status. The business relies on the drug Skyclarys, which forms a closed therapy ecosystem. Tracking the consolidated gross margin on GURU.Markets, we note that 91.60 determines this parameter level.

RETA (Reata) Gross Margin history from 07/04/2022 to 10/07/2023

Comprehensive metric breakdowns and analytics for Reata (RETA)

- market price and analyst price targets:
Fundamental valuation:Reata Pharmaceuticals
Manufactured product of Reata Pharmaceuticals Inc

The outsourcing model of Reata Pharmaceuticals shifts production to external contractors, making the control of direct costs critically important. The gross margin, equal to 91.60, measures the profit share after deducting the cost of goods sold, reflecting the efficiency of contract management. Steady growth of this ratio confirms operational resilience, while any anomalies in the target gross margin signal risks of reporting manipulation.